Adverse reactions in the treatment of patients with non-tuberculous lung mycobacterial pulmonary disease and the possibility of their solution
- Authors: Vladimirova E.B.1, Shmelev E.I.1, Zaytseva A.S.1, Kasimtseva S.A.1, Shchepikhin E.I.1, Smirnova T.G.1, Makaryants N.N.1
-
Affiliations:
- Central Research Institute of Tuberculosis
- Issue: Vol 96, No 11 (2024): Инфекционные заболевания
- Pages: 1049-1055
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/275835
- DOI: https://doi.org/10.26442/00403660.2024.11.202992
- ID: 275835
Cite item
Full Text
Abstract
Aim. To study the adverse reactions that develop as a result of complex antibiotic therapy in patients with non-tuberculous lung mycobacterial (NTML) and to determine methods for their elimination without compromising the effectiveness of NTML treatment.
Materials and methods. Examined 147 patients with confirmed NTML, for which they received treatment in accordance with the results of drug susceptibility of the pathogen. Before and during treatment, a study of clinical, biochemical blood tests, urinalysis, electrocardiogram, external respiration function, ultrasound of the abdominal organs and kidneys was performed.
Results. Under the conditions of antimicrobial therapy (AMT) for non-tuberculous mycobacteriosis of the lungs, 41 (27.9%) patients developed adverse drug reaction (ADR). The most frequent adverse reactions were: allergic reactions in the form of urticaria, nausea, vomiting, arthralgia, nephro- and ototoxic reactions; 34 (82.9%) patients required treatment adjustment without discontinuation of AMT, and only in 7 (17.1%) cases, AMT was discontinued. A full course of multicomponent AMT was completed in 124 (84.4%) patients with NTML. An algorithm for monitoring therapy in NTML patients from the standpoint of preventing ADR has been developed. The categories of patients with potential risks of developing ADR under AMT were determined. Patients without the development of ADR had a positive radiological dynamics in 27.9% of cases, sputum conversion – in 42%. Patients with ADR had positive clinical dynamics in 39% of cases, radiological – in 31.7% of cases, sputum conversion – in 36.6% of cases.
Conclusion. The incidence of ADR development remains high when complex AMT is administered to patients with NTML. The patient's comorbid background is the main risk factor for the development of ADR when prescribing multicomponent AMT. A multivariate analysis of the effectiveness of treatment in NTML patients showed comparable data among patients taking complex AMT and receiving only alternative therapies. The success of NTML treatment depends on a comprehensive personalized approach.
Full Text
##article.viewOnOriginalSite##About the authors
Elena B. Vladimirova
Central Research Institute of Tuberculosis
Author for correspondence.
Email: velebor@mail.ru
ORCID iD: 0000-0002-5050-5360
канд. мед. наук, науч. сотр. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения
Russian Federation, MoscowEvgene I. Shmelev
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0002-1908-5601
д-р мед. наук, проф., гл. науч. сотр.
Russian Federation, MoscowAnna S. Zaytseva
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0001-7155-5730
канд. мед. наук, ст. науч. сотр. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения
Russian Federation, MoscowSvetlana A. Kasimtseva
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0001-5303-443X
канд. мед. наук, науч. сотр. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения
Russian Federation, MoscowEvgeniy I. Shchepikhin
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0002-9146-0904
аспирант отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения
Russian Federation, MoscowTatiana G. Smirnova
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0003-2886-1745
канд. мед. наук, зав. отд. микробиологии
Russian Federation, MoscowNatalia N. Makaryants
Central Research Institute of Tuberculosis
Email: velebor@mail.ru
ORCID iD: 0000-0002-6390-8759
д-р мед. наук, вед. науч. сотр., зав. отд. дифференциальной диагностики туберкулеза легких и экстракорпоральных методов лечения, врач-пульмонолог высшей категории
Russian Federation, MoscowReferences
- Zhou Y, Mu W, Zhang J, et al. Global prevalence of non-tuberculous mycobacteria in adults with non-cystic fibrosis bronchiectasis 2006–2021: a systematic review and meta-analysis. BMJ open. 2022;12(8):e055672. doi: 10.1136/bmjopen-2021-055672
- Владимирова Е.Б., Шмелев Е.И., Зайцева А.С., и др. Нетуберкулезный микобактериоз легких – возможности диагностики в практике пульмонолога. Терапевтический архив. 2019;91(11):26-31 [Vladimirova EB, Shmelev EI, Zaitseva AS, et al. Non-tuberculous mycobacteriosis of the lungs – diagnostic possibilities in the practice of a pulmonologist. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(11):26-31 (in Russian)]. doi: 10.26442/00403660.2019.11.000306
- Muñoz-Egea MC, Carrasco-Antón N, Esteban J. State-of-the-art treatment strategies for nontuberculous mycobacteria infections. Expert Opin Pharmacother. 2020;21(8):969-81. doi: 10.1080/14656566.2020.1740205
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56:2000535. doi: 10.1183/13993003.00535-2020
- Jenkins PA, Campbell I, Banks J, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicini and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;7(63):627-34. doi: 10.1136/thx.2007.087999
- Зимина В.Н., Дегтярева С.Ю., Белобородова Е.Н., и др. Микобактериозы: современное состояние проблемы. Клиническая микробиология и антимикробная химиотерапия. 2017;19(4):276-82 [Zimina VN, Degtjareva SJu, Beloborodova EN, et al. Mycobacterioses: the current state of the problem. Klinicheskaia mikrobiologiia i antimikrobnaia himioterapiia. 2017;19(4):276-82 (in Russian)].
- Kim JY, Kim NY, Jung HW, et al. Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease. BMC Pulm Med. 2022;22(1):269. doi: 10.1186/s12890-022-02063-2
- Kamii Y, Nagai H, Kawashima M, et al. Adverse reactions associated with long-term drug administration in Mycobacterium avium complex lung disease. Int J Tuberc Lung Dis. 2018;22(12):1505-10. doi: 10.5588/ijtld.18.0171
- Ozawa T, Namkoong H, Takaya R, et al. Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system. BMC Infect Dis. 2022;22(1):580. doi: 10.1186/s12879-022-07568-z
- WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO. 1972;498.
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Charles L. Daley1, 2, 26. Clin Infect Dis. 2020;71(4):905-13. doi: 10.1093/cid/ciaa1125
